Overview

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anti-Obesity Agents
Islet Amyloid Polypeptide
Phentermine
Pramlintide
Sibutramine